Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1275-1282

  Bulitta, J B ^a,b   Landersdorfer, C B ^a,b   Huttner S J ^a   Drusano, G L ^b   Kinzig, M ^a   Holzgrabe, U ^c   Stephan, U ^a,d   Sorgel F ^a,d  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME;

ADOLESCENT; ADULT; ALLOMETRY; ARTICLE; BLOOD SAMPLING; BODY SIZE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; SCHOOL CHILD; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; POPULATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77149124236     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00936-09     Document Type: Article

References (80)

1. Alou, L., L. Aguilar, D. Sevillano, M. J. Gimenez, O. Echeverria, M. L. Gomez-Lus, and J. Prieto. 2005. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J. Antimicrob. Chemother. 55:209-213.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
3. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
4. Anonymous. 1998. Cystic fibrosis foundation patient registry 1997 annual data report. Cystic Fibrosis Foundation, Bethesda, MD.
5. Armstrong, G. C., R. Wise, R. M. Brown, and J. Hancox. 1981. Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. Antimicrob. Agents Chemother. 20:356-358.
6. Aronoff, S. C., and J. D. Klinger. 1985. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis. J. Antimicrob. Chemother. 15:545-549.
7. Arvidsson, A., G. Alvan, and B. Strandvik. 1983. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatr. Scand. 72:293-294.
8. Bakker, W., A. A. Vinks, J. W. Mouton, P. de Jonge, J. G. Verzijl, and H. G. Heijerman. 1993. Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study. Ned. Tijdschr. Geneeskd. 137:2486-2491.
9. Bauer, R. J. 2008. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis, Berkeley, CA.
10. Beal, S. L., A. J. Boeckmann, L. B. Sheiner, and the NONMEM Project Group. 1999. NONMEM users guides, version 5. University of California at San Francisco, San Francisco, CA.
11. Berg, U., E. Kusoffsky, and B. Strandvik. 1982. Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatr. Scand. 71:833-838.
12. Blumer, J. L., R. C. Stern, J. D. Klinger, T. S. Yamashita, C. M. Meyers, A. Blum, and M. D. Reed. 1985. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Am. J. Med. 79:37-46.
13. Bosso, J. A., C. R. Bonapace, P. A. Flume, and R. L. White. 1999. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 19: 620-626.
14. Bulitta, J., S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, and F. Sörgel. 2005. Cystic fibrosis patients are pharmacokinetically comparable to healthy volunteers, abstr. 1923. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
15. Bulitta, J. B., S. B. Duffull, C. B. Landersdorfer, G. L. Drusano, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, and F. Sörgel. 2006. Pharmacodynamic comparison of cystic fibrosis patients and healthy volunteers by population pharmacokinetics (PK) and Monte Carlo simulation, poster W4056. Abstr. Am. Assoc. Pharm. Sci. Annu. Meet., San Antonio, TX, 29 October to 2 November 2006.
16. Bulitta, J. B., S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507.
17. Bulitta, J. B., S. B. Duffull, C. B. Landersdorfer, M. Kinzig, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel. 2009. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Diagn. Microbiol. Infect. Dis. 65:130-141.
18. Bulitta, J. B., C. B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel. 2009. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Antimicrob. Agents Chemother. 53:3462-3471.
19. Canton, R., N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Alvarez, A. Salcedo, A. Oliver, and E. Garcia-Quetglas. 2005. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 11:690-703.
20. Cappelletty, D. M., S. L. Kang, S. M. Palmer, and M. J. Rybak. 1995. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob. Agents Chemother. 39:1797-1801.
21. Cheymol, G. 2000. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin. Pharmacokinet. 39:215-231.
22. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
23. David, T. J., and J. Devlin. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lancet i:1454-1455.
24. Doring, G., S. P. Conway, H. G. Heijerman, M. E. Hodson, N. Hoiby, A. Smyth, and D. J. Touw. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767.
25. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
26. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
27. Drusano, G. L., H. C. Standiford, B. Fitzpatrick, J. Leslie, P. Tangtatsawasdi, P. Ryan, B. Tatem, M. R. Moody, and S. C. Schimpff. 1984. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob. Agents Chemother. 26: 388-393.
28. Frederiksen, B., S. Lanng, C. Koch, and N. Hoiby. 1996. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21:153-158.
29. George, R. B., Y. Cartier, A. G. Casson, and P. Hernandez. 2006. Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis. Can. Respir. J. 13:215-218.
30. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951.
31. Green, B., and S. B. Duffull. 2004. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol. 58:119-133.
32. Harding, S. M., A. J. Monro, J. E. Thornton, A. J. Munro, and M. I. J. Hogg. 1981. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J. Antimicrob. Chemother. 8(Suppl. B):262-272.
33. Hedman, A., Y. Adan-Abdi, G. Alvan, B. Strandvik, and A. Arvidsson. 1988. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin. Pharmacokinet. 15:57-65.
34. Hoiby, N. 1993. Antibiotic therapy for chronic infection of pseudomonas in the lung. Annu. Rev. Med. 44:1-10.
35. Holford, N. H. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332.
36. Hubert, D., E. Le Roux, T. Lavrut, B. Wallaert, P. Scheid, D. Manach, D. Grenet, I. Sermet-Gaudelus, S. Ramel, C. Cracowski, A. Sardet, N. Wizla, E. Deneuville, and R. Garraffo. 2009. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob. Agents Chemother. 53:3650-3656.
37. Hüttner, S., J. B. Bulitta, M. Kinzig, U. Holzgrabe, U. Stephan, and F. Sörgel. 2009. Population pharmacokinetics and optimized dosage regimens of ceftazidime in cystic fibrosis patients and healthy volunteers, abstr. 2798. Abstr. Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland.
38. James, W. 1976. Research on obesity. Her Majesty's Stationery Office, London, United Kingdom.
39. Janmahasatian, S., S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne, and B. Green. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44: 1051-1065.
40. Kemmerich, B., H. Warns, H. Lode, K. Borner, P. Koeppe, and H. Knothe. 1983. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob. Agents Chemother. 24:333-338.
41. Kercsmar, C. M., R. C. Stern, M. D. Reed, C. M. Myers, D. Murdell, and J. L. Blumer. 1983. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J. Antimicrob. Chemother. 12(Suppl. A):289-295.
42. Kuzemko, J., and C. Crawford. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lancet ii:385.
43. Leary, R., R. W. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. IEEE Computer Society, Bethesda, MD.
44. Leeder, J. S., M. Spino, A. F. Isles, A. M. Tesoro, R. Gold, and S. M. MacLeod. 1984. Ceftazidime disposition in acute and stable cystic fibrosis. Clin. Pharmacol. Ther. 36:355-362.
45. Livermore, D. M., S. Mushtaq, Y. Ge, and M. Warner. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406.
46. Manno, G., M. Cruciani, L. Romano, S. Scapolan, M. Mentasti, R. Lorini, and L. Minicucci. 2005. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Int. J. Antimicrob. Agents 25:193-197.
47. Martini, N., M. Agostini, G. Barlocco, L. Bozzini, L. Castellani, A. Messori, G. Scroccaro, and G. Mastella. 1984. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis. J. Clin. Hosp. Pharm. 9:303-309.
48. Miller, M. E., and D. M. Kornhauser. 1994. Bromide pharmacokinetics in cystic fibrosis. Arch. Pediatr. Adolesc. Med. 148:266-271.
49. Morgan, D. J., and K. M. Bray. 1994. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet. 26:292-307.
50. Mouton, J., A. Horrevorts, S. Overbeek, et al. 1993. Pharmacokinetics of ceftazidime during continuous and intermittent infusion in adult cystic fibrosis patients, p. 88-99. In J. W. Mouton (ed.), Pharmacokinetic and pharmacodynamic studies of betalactam antibiotics in volunteers and patients with cystic fibrosis. University of Rotterdam, Rotterdam, the Netherlands.
51. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
52. Mouton, J. W., A. M. Horrevorts, P. G. Mulder, E. P. Prens, and M. F. Michel. 1990. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob. Agents Chemother. 34:2307-2311.
53. Mouton, J. W., N. Punt, and A. A. Vinks. 2005. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin. Ther. 27:762-772.
54. Norrby, S. R. 1983. Ceftazidime in clinical practice - a summary. J. Antimicrob. Chemother. 12(Suppl. A):405-408.
55. Paap, C. M., and M. C. Nahata. 1990. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet. 19:280-318.
56. Padoan, R., A. Brienza, R. M. Crossignani, G. Lodi, A. Giunta, B. M. Assael, F. Granata, E. Passarella, P. A. Vallaperta, and L. Xerri. 1983. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J. Pediatr. 103:320-324.
57. Paulfeuerborn, W., H. J. Muller, K. Borner, P. Koeppe, and H. Lode. 1993. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob. Agents Chemother. 37:1835-1841.
58. Permin, H., C. Koch, N. Hoiby, H. O. Christensen, A. F. Moller, and S. Moller. 1983. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J. Antimicrob. Chemother. 12(Suppl. A):313-323.
59. Rappaz, I., L. A. Decosterd, J. Bille, M. Pilet, N. Belaz, and M. Roulet. 2000. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur. J. Pediatr. 159:919-925.
60. Reed, M. 1997. The pathophysiology and treatment of cystic fibrosis. J. Pediatr. Pharm. Pract. 2:285-308.
61. Reed, M. D., R. C. Stern, C. A. O'Brien, D. A. Crenshaw, and J. L. Blumer. 1987. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob. Agents Chemother. 31:698-702.
62. Rey, E., J. M. Treluyer, and G. Pons. 1998. Drug disposition in cystic fibrosis. Clin. Pharmacokinet. 35:313-329.
63. Riethmueller, J., S. Junge, T. W. Schroeter, K. Kuemmerer, P. Franke, M. Ballmann, A. Claass, S. Broemme, R. Jeschke, A. Hebestreit, D. Staab, K. Koetz, G. Doering, and M. Stern. 15 September 2009. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection. doi:10.1007/s15010-009-8116-5.
64. Robinson, C. A., R. J. Kuhn, J. Craigmyle, M. I. Anstead, and J. E. Kanga. 2001. Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis. Pharmacotherapy 21:1320-1324.
65. Sörgel, F., U. Stephan, H. C. Dominick, H. G. Wiesemann, H. B. Böwing, and C. Stehr. 1985. Pharmacokinetics of ceftazidime in patients with cystic fibrosis, abstr. 24. Abstr. Eur. Workshop Cystic Fibrosis, Jerusalem, Israel.
66. Sörgel, F., U. Stephan, C. Stehr, R. Seelmann, M. Rey, U. Koch, H. G. Wiesemann, H. C. Dominick, and B. Gottschalk. 1986. High dose treatment with antibiotics in patients with cystic fibrosis (CF)?, abstr. 614. Abstr. 26th Intersci. Conf. Antimicrob. Agents Chemother., New Orleans, LA.
67. Sorgel, F., U. Stephan, H. G. Wiesemann, B. Gottschalk, C. Stehr, M. Rey, H. B. Bowing, H. C. Dominick, and M. Geldmacher von Mallinckrodt. 1987. High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection 15:385-396.
68. Strandvik, B., A. S. Malmborg, H. Alfredson, and A. Ericsson. 1983. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J. Antimicrob. Chemother. 12(Suppl. A):283-287.
69. Taccetti, G., S. Campana, and L. Marianelli. 1999. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis Microbiology. Eur. J. Epidemiol. 15:85-88.
70. Tjandramaga, T. B., A. Van Hecken, A. Mullie, R. Verbesselt, P. J. De Schepper, and L. Verbist. 1982. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob. Agents Chemother. 22:237-241.
71. Touw, D. J., A. A. Vinks, J. W. Mouton, and A. M. Horrevorts. 1998. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin. Pharmacokinet. 35:437-459.
72. Turner, A., S. J. Pedler, F. Carswell, G. R. Spencer, and D. C. Speller. 1984. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J. Antimicrob. Chemother. 14:521-527.
73. Vaisman, N., P. B. Pencharz, M. Corey, G. J. Canny, and E. Hahn. 1987. Energy expenditure of patients with cystic fibrosis. J. Pediatr. 111:496-500.
74. Viaene, E., H. Chanteux, H. Servais, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2002. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46:2327-2332.
75. Vinks, A. A., R. W. Brimicombe, H. G. Heijerman, and W. Bakker. 1997. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother. 40:125-133.
76. Vinks, A. A., D. J. Touw, H. G. Heijerman, M. Danhof, G. P. de Leede, and W. Bakker. 1994. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther. Drug Monit. 16:341-348.
77. Vinks, A. A., R. N. van Rossem, R. A. Mathot, H. G. Heijerman, and J. W. Mouton. 2007. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother. 51:3049-3055.
78. Walstad, R. A., K. B. Hellum, S. Blika, L. G. Dale, T. Fredriksen, K. I. Myhre, and G. R. Spencer. 1983. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J. Antimicrob. Chemother. 12(Suppl. A):275-282.
79. West, G. B., J. H. Brown, and B. J. Enquist. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677-1679.
80. West, G. B., J. H. Brown, and B. J. Enquist. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.